NCT02439359View on ClinicalTrials.gov

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Interventions
DRUG

CF-301

Dose escalation

DRUG

Placebo

Trial Locations (2)

66219

Lenexa

Unknown

Cf 301-105, Omaha

Sponsors

Lead Sponsor

ContraFect
All Listed Sponsors
lead

ContraFect

INDUSTRY